Skip to main content
Amoy Diagnostics Co.,Ltd. logo

Amoy Diagnostics Co.,Ltd. — Investor Relations & Filings

Ticker · 300685 ISIN · CNE1000034D3 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,088 across all filing types
Latest filing 2020-04-16 Audit Report / Informat…
Country CN China
Listing Shenzhen Stock Exchange 300685

About Amoy Diagnostics Co.,Ltd.

https://www.amoydx.com

Amoy Diagnostics Co., Ltd. specializes in the development and commercialization of molecular diagnostic products for precision oncology. The company provides a comprehensive portfolio of testing kits designed to identify genetic mutations and biomarkers essential for personalized cancer treatment. Its core technology platforms include the proprietary ADx-ARMS, Super-ARMS, and specialized Next-Generation Sequencing (NGS) solutions. AmoyDx focuses on companion diagnostics (CDx), collaborating extensively with global pharmaceutical companies to integrate diagnostic testing into clinical drug development and patient management. Key products cover a wide range of solid tumors, including lung, colorectal, and breast cancers, facilitating targeted therapy selection and monitoring. The company maintains rigorous quality standards, with numerous products receiving regulatory approvals for clinical use in multiple international markets.

Recent filings

Filing Released Lang Actions
中信证券股份有限公司关于公司2019年年度跟踪报告
Audit Report / Information Classification · 95% confidence The document is titled as a "2019 年年度跟踪报告" (2019 Annual Tracking Report) issued by 中信证券股份有限公司 (CITIC Securities Co., Ltd.) regarding 厦门艾德生物医药科技股份有限公司 (Xiamen Aide Biomedical Technology Co., Ltd.). It details the sponsor's work overview, supervision of fundraising, governance, regulatory issues, and compliance with various regulatory bodies including the China Securities Regulatory Commission (CSRC). The content includes detailed descriptions of regulatory inspections, supervisory actions, and corrective measures taken during the year 2019. The document is comprehensive and contains substantive information about the sponsor's monitoring and regulatory compliance activities over the year, which aligns with the nature of an Audit Report / Information (AR) rather than a full Annual Report (10-K) or a simple announcement. It is not a report publication announcement (RPA) because it contains detailed content rather than just a notice. It is not a regulatory filing (RNS) because it is a detailed report on audit and supervisory activities. Therefore, the best classification is Audit Report / Information (AR). FY 2019
2020-04-16 Chinese
独立董事2019年度述职报告（朱明华）
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director 2019 Annual Work Report" for Xiamen Aide Biomedical Technology Co., Ltd. It is a detailed report by an independent director summarizing attendance at board meetings, opinions on company matters, committee work, inspections, investor protection efforts, and training during the 2019 fiscal year. The content focuses on the director's duties and activities rather than financial results or audit opinions. It is not an annual report (10-K), audit report (AR), or management report (MDA). It is also not a brief announcement or voting result. The document is a formal report by a board member on their activities and responsibilities, which fits best under Board/Management Information (MANG). The document length is 2843 characters, which is consistent with a detailed director report rather than a short announcement. Therefore, the classification is MANG with high confidence.
2020-04-13 Chinese
独立董事关于相关事项的事前认可意见
Regulatory Filings Classification · 95% confidence The document is a statement from independent directors providing prior approval for the appointment of the 2020 audit firm for the company. It references regulatory guidelines related to independent directors and audit practices, and it is dated April 3, 2020. The content focuses on the approval of the audit firm rather than presenting an audit report or financial statements. The document length is short (508 characters), and it does not contain actual financial data or audit results. Therefore, it is not an Audit Report (AR) but rather a regulatory or compliance-related filing. Given the nature of the document as an official opinion or certification related to audit matters, it fits best under Regulatory Filings (RNS).
2020-04-13 Chinese
2019年度监事会工作报告
Audit Report / Information Classification · 95% confidence The document is titled '2019 年度监事会工作报告' which translates to '2019 Supervisory Board Work Report'. It details the supervisory board's activities, meetings, oversight of company operations, financial status, compliance with laws and regulations, and internal controls for the year 2019. It includes specific references to monitoring financial reports, internal control self-evaluation, and compliance with regulatory requirements. The document is a detailed report on the supervisory board's work and oversight during the fiscal year, not an announcement or a brief summary. It is not a full annual report (10-K) but a specific supervisory board report, which aligns with the category of Audit Report / Information (AR) as it includes audit-related oversight and internal control evaluations. The document length is 3385 characters, which is relatively short but contains substantive content typical of an audit or supervisory report rather than a mere announcement or certification. Therefore, the best fit is Audit Report / Information (AR). FY 2019
2020-04-13 Chinese
2019年年度报告
Annual Report Classification · 100% confidence The document is titled as the "2019 Annual Report" of 厦门艾德生物医药科技股份有限公司 (Amoy Diagnostics Co., Ltd.). It contains detailed sections including company overview, financial data, business summary, risk factors, and operational analysis. The text includes comprehensive financial figures, business descriptions, and management discussions typical of a full annual report. The document length is substantial (15,000 characters), and it is not a brief announcement or a certification. Therefore, it fits the definition of an Annual Report (10-K). FY 2019
2020-04-13 Chinese
中信证券股份有限公司关于公司部分募集资金投资项目结项并将节余募集资金永久补充流动资金的核查意见
Capital/Financing Update Classification · 95% confidence The document is a detailed verification opinion from a sponsoring institution (中信证券股份有限公司) regarding the completion of certain fundraising investment projects and the permanent supplementation of surplus raised funds into working capital by 厦门艾德生物医药科技股份有限公司. It references regulatory guidelines on fundraising management, details the fundraising amount, usage, surplus, and approvals by the board, supervisory committee, and independent directors. The document includes audit opinions and compliance confirmations but does not contain full financial statements or quarterly/yearly financial results. It is a formal verification and compliance report related to fundraising usage rather than a full annual report, interim report, or earnings release. It is not a brief announcement but a substantive verification opinion. This fits best under the category of Capital/Financing Update (CAP), as it concerns the use and management of raised capital and related approvals.
2020-04-13 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.